What to check up on during Wegovy treatment

What a good Wegovy check-up actually reviews

A common misconception is that check-ups exist mainly to renew the prescription. They do that, but a thorough review covers considerably more ground, and it's worth knowing what to expect so you can come prepared.

Your prescriber should be looking at weight change since the last appointment, framed as a trend rather than a single weigh-in. They'll want to know how you've been tolerating the current dose: nausea, constipation, reflux, fatigue and any injection-site irritation are the side effects worth flagging, as described by the NHS semaglutide patient guide. If those symptoms have been mild and are settling, that's useful information. If they've persisted through a full dose period, it shapes whether an increase is appropriate.

Blood pressure is worth checking regularly during treatment, weight loss tends to lower it, which is usually good, but occasionally medication that was calibrated to your earlier weight needs adjusting by your GP. Mood and energy are legitimate topics too. Some people feel better as weight comes down; others go through a difficult patch. Either is worth mentioning. And if you've had any episodes of severe stomach pain, your prescriber needs to know promptly rather than at the next scheduled slot, that symptom warrants same-day clinical attention.

The review should also revisit the lifestyle changes you're making alongside treatment. Wegovy works best when diet and activity are genuinely part of the picture, and a check-up is the right place to troubleshoot barriers rather than assume everything is ticking over.

What you can track yourself between appointments

Formal check-ups are only part of the monitoring picture. What you observe day-to-day is genuinely useful clinical data, and the more precisely you can describe it, the more efficient your reviews become.

Weighing yourself consistently (same time of day, same conditions) once a week gives a cleaner trend than daily readings, which bounce with hydration and other variables. Some people find a treatment diary helpful for logging weight, symptoms and how appetite has shifted through the dose cycle. Tracking this way means you arrive at a check-up with a narrative rather than a vague impression.

Injection sites are worth observing too. Rotating between abdomen, thigh and upper arm reduces local reactions; if one site is consistently more irritated than others, that's worth raising. The Wegovy pen device itself should be inspected before each use, check the solution is clear and colourless, that the pen hasn't been damaged, and that storage conditions have been maintained. If you've ever had cause to verify a batch, the batch number checker explains what to look for.

Hydration matters more than people expect on GLP-1 treatment. Appetite suppression can reduce fluid intake alongside food intake, and the body-composition changes that come with significant weight loss are worth monitoring in their own right. Drink enough water to keep urine pale, especially through any period of GI side effects.

Deciding whether your current check-up structure is sufficient

This is the actual decision the keyword points to, and it's worth being honest about. Not all private prescribing services offer the same depth of review. Some carry out a perfunctory repeat without examining response or symptoms in detail. If your check-ups feel like a formality rather than a clinical conversation, that's a reasonable signal to evaluate your provider.

Under NICE's appraisal of semaglutide (TA875), ongoing review is built into the framework: if less than five percent of body weight has been lost after six months on the maintenance dose, continuing treatment is reviewed. That threshold isn't punitive, it's a safeguard that protects people from prolonged treatment that isn't working for them. A check-up structure that never asks this question is missing something important.

For people who have moved from one provider to another, or who started treatment elsewhere and want a more rigorous review process, there are practical questions worth asking: Does your prescriber personally review your information at each repeat? Is dose escalation evidence-based rather than automatic? Can you reach clinical support between scheduled appointments if a concern comes up? Information about how our prescribers work through this process is on the about us page. The cost of treatment is one consideration, and it's worth understanding what the treatment pricing at different services actually includes, a check-up that exists on paper only is not the same as one that changes your care.

When to contact a prescriber before your next scheduled check-up

Scheduled reviews are planned around the titration timetable. Urgent symptoms don't wait for the calendar, and knowing which ones need faster attention is a practical safety skill.

Severe or persistent stomach pain (especially if it radiates toward the back) requires same-day medical attention. This is the symptom pattern associated with pancreatitis, a known but uncommon risk with GLP-1 medicines, and one the MHRA specifically flagged in a January 2026 Drug Safety Update. Symptoms of gallbladder problems (sharp upper-right abdominal pain, particularly after eating), signs of significant dehydration following prolonged vomiting or diarrhoea, and any signs of an allergic reaction all fall into the same category: contact your prescriber or seek medical help promptly, and report suspected side effects via the MHRA's Yellow Card scheme.

Questions about travel (including whether you can take your pens in checked luggage) or about skin and body changes like neck skin changes during treatment don't need urgent escalation, but they're worth raising at your next check-up rather than researching in isolation. Our prescribers can talk through what's expected and what isn't. If you'd like that conversation, speak to our prescribers through a free consultation and get a structured review from the start.